Related Experiment Videos
Transforming growth factor-beta 2 is an autocrine growth inhibitory factor for the MOSER human colon carcinoma cell
1University of Texas Health Science Center, Dental Branch, Houston 77225.
Abstract:
The MOSER human colon carcinoma cell line is significantly growth inhibited by exogenous transforming growth factor-beta (TGF-beta). The secretion of TGF-beta by these cells was examined to determine if endogenous TGF-beta might also regulate MOSER cell growth. MOSER cells secreted 11 ng TGF-beta/10(6) cells, 24% of which was in the active form. Blocking antibodies specific for TGF-beta 2 stimulated growth 1.4-fold, while TGF-beta 1 specific antibodies were without effect. Treatment of MOSER cells with the differentiation agent, N,N-dimethylformamide (DMF), inhibited cell growth and resulted in an 8-fold increase in secreted TGF-beta (20% active). Only antibodies specific for TGF-beta 2 were able to reverse the growth inhibitory effect of DMF on these cells. Therefore, TGF-beta 2 acted as a negative autocrine inhibitory factor for MOSER cells and the growth inhibitory effects of DMF were mediated by the increased secretion of active TGF-beta 2.
Insights
Transforming growth factor-beta 2 (TGF-beta 2) acts as a negative autocrine factor in MOSER colon cancer cells. Its increased secretion mediates growth inhibition by differentiation agents like DMF.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- The MOSER human colon carcinoma cell line exhibits sensitivity to exogenous transforming growth factor-beta (TGF-beta).
- Investigating endogenous TGF-beta secretion is crucial to understand its role in regulating MOSER cell proliferation.
Purpose of the Study:
- To determine if endogenous TGF-beta regulates MOSER cell growth.
- To elucidate the specific role of TGF-beta isoforms in colon carcinoma cell behavior.
- To understand the mechanism by which differentiation agents inhibit cell growth.
Main Methods:
- Quantification of TGF-beta secretion by MOSER cells.
- Assessment of active TGF-beta levels.
- Inhibition of TGF-beta signaling using isoform-specific blocking antibodies.
- Treatment with N,N-dimethylformamide (DMF) and subsequent analysis of TGF-beta secretion and cell growth.
Main Results:
- MOSER cells secrete TGF-beta, with 24% in active form.
- Blocking TGF-beta 2 antibodies stimulated cell growth by 1.4-fold, indicating an inhibitory role.
- DMF treatment inhibited cell growth and increased TGF-beta secretion 8-fold (20% active).
- Only TGF-beta 2 specific antibodies reversed DMF-induced growth inhibition.
Conclusions:
- TGF-beta 2 functions as a negative autocrine inhibitory factor for MOSER colon carcinoma cells.
- The growth inhibitory effects of DMF are mediated through increased secretion of active TGF-beta 2.